```html

Opsoclonus‑Myoclonus Syndrome (OMS) – A Patient‑Friendly Guide

Overview

Opsoclonus‑myoclonus syndrome (OMS) is a rare neuro‑immunological disorder characterized by chaotic, rapid eye movements (opsoclonus) combined with brief, involuntary muscle jerks (myoclonus). The condition often includes ataxia (loss of coordination), sleep disturbances, and neurocognitive changes. OMS can affect children and adults, but it is most commonly seen in infants and preschool‑age children.

Prevalence: Epidemiologic studies estimate an incidence of 1–2 cases per 1 million children per year in the United States, with a slightly higher frequency in Europe (Maddison et al., 2015). Adult cases are even rarer, accounting for fewer than 100 published case series worldwide.

Who it affects:

• Children: 70–80 % of reported cases occur before age 5.
• Adults: Usually linked to an underlying malignancy (paraneoplastic OMS) or autoimmune disease.
• Both sexes are affected equally.

Symptoms

OMS presents with a cluster of neurological signs. Not every patient shows all features, but the core triad is opsoclonus, myoclonus, and ataxia.

Eye‑movement abnormalities (Opsoclonus)

• Chaotic saccades: Rapid, multidirectional eye jumps that are not suppressible.
• Absence of fixation: Inability to hold gaze on a single point.
• Often described as “dancing eyes.”

Myoclonus

• Quick, shock‑like jerks affecting the face, arms, trunk, or legs.
• Occurs spontaneously or in response to light touch or sound.
• May be more noticeable when the patient is at rest.

Ataxia

• Unsteady gait, frequent stumbling, and difficulty with fine motor tasks (e.g., buttoning a shirt).
• Often accompanied by a broad-based stance.

Additional neurological and systemic signs

• Behavioral changes: Irritability, anxiety, mood swings.
• Sleep disturbances: Insomnia or fragmented sleep.
• Speech problems: Slurred or slowed speech (dysarthria).
• Cognitive impairment: Attention deficits or developmental delay in children.
• Autonomic symptoms: Sweating, tachycardia, or blood pressure variability (rare).

Causes and Risk Factors

OMS is considered an autoimmune-mediated disorder, either paraneoplastic (cancer‑related) or post‑infectious/idiopathic. The underlying mechanism involves antibodies that mistakenly target neuronal surface antigens, especially in the cerebellum and brainstem.

Paraneoplastic OMS (Adults)

• Neuroblastoma – most common in children (≈ 50 % of pediatric cases).
• Small‑cell lung carcinoma, breast cancer, ovarian teratoma – reported in adult OMS.
• Antibodies frequently found: anti‑Hu, anti‑Ri (ANNA‑2), anti‑Yo, and anti‑NMDAR.

Post‑infectious/Idiopathic OMS (Children)

• Recent viral infections (e.g., influenza, EBV, enterovirus) have been documented.
• Occasionally follows bacterial infections or vaccination, though causality remains uncertain.

Risk Factors

• Age < 5 years (children) or > 30 years (adult paraneoplastic cases).
• Presence of an underlying tumor (especially neuroblastoma in kids).
• Genetic predisposition to autoimmune disease (family history of lupus, thyroiditis, etc.).
• Recent infection or immunization (temporal association, not proof of cause).

Diagnosis

Because OMS is rare and its symptoms overlap with other movement disorders, a systematic approach is essential.

Clinical assessment

1. History: Onset pattern, recent infections, weight loss, or cancer‑related symptoms.
2. Neurological exam: Document opsoclonus (eye‑movement video recordings are helpful), myoclonus distribution, and ataxia severity.

Laboratory and imaging studies

• Serum and CSF autoantibody panels: Test for anti‑Ri, anti‑Hu, anti‑Yo, anti‑NMDAR, GAD65, and others. Positive antibodies support an autoimmune etiology (Graus et al., 2020).
• CSF analysis: Often shows mild lymphocytic pleocytosis, elevated protein, or oligoclonal bands.
• Neuroimaging:
  • MRI of brain and spine – typically normal, but may reveal cerebellar inflammation.
  • Whole‑body MRI, CT, or PET‑CT when a paraneoplastic source is suspected.
• Oncologic work‑up (children): Abdominal ultrasound, MIBG scan, or CT to search for neuroblastoma.

Diagnostic criteria (Modified from the International Pediatric OMS Consortium)

• Presence of opsoclonus + myoclonus + ataxia.
• Exclusion of alternative diagnoses (e.g., epilepsy, CNS infection).
• Supportive evidence: positive autoantibodies or identification of an associated tumor.

Treatment Options

Early, aggressive immunotherapy improves neurological outcomes and reduces long‑term disability. Treatment is usually multidisciplinary, involving neurologists, oncologists (if a tumor is present), physiotherapists, and psychologists.

First‑line immunotherapy

• Corticosteroids (e.g., methylprednisolone 30 mg/kg IV daily × 3 days, then oral taper). Benefits: rapid symptom reduction.
• Intravenous immunoglobulin (IVIG) – 2 g/kg divided over 2–5 days; repeated every 4–6 weeks if needed.
• Plasma exchange (PLEX) – 5–7 exchanges over 10–14 days; useful when antibodies are high‑titer.

Second‑line agents (for refractory or relapsing disease)

• Rituximab – anti‑CD20 monoclonal antibody; 375 mg/m² weekly for 4 weeks.
• Mycophenolate mofetil – 600 mg/m² BID; often combined with steroids.
• Cyclophosphamide – used sparingly due to toxicity; 750 mg/m² IV monthly for 6 months.

Oncologic treatment (if a tumor is identified)

Complete surgical resection of neuroblastoma or chemotherapy/radiation per oncologic protocols dramatically improves neurological recovery (CDC Cancer Guidelines).

Supportive and rehabilitative care

• Physical & occupational therapy – focus on balance, gait training, fine‑motor skills.
• Speech therapy – for dysarthria or language delays.
• Psychological support – cognitive‑behavioral therapy for anxiety, mood swings, and school‑related challenges.
• Sleep hygiene measures – regular bedtime routine, limited screen time.

Lifestyle modifications

• Avoidance of triggers that may worsen myoclonus (e.g., sudden loud noises, bright flashing lights).
• Maintain a balanced diet rich in omega‑3 fatty acids, which have modest anti‑inflammatory effects.
• Stay up‑to‑date on vaccinations; although OMS can follow infection, the benefits of immunization outweigh the rare risk.

Living with Opsoclonus‑Myoclonus Syndrome

OMS can be a chronic condition with periods of remission and relapse. The following strategies help patients and families cope:

• Regular follow‑ups: Neurology appointments every 3–6 months, or sooner if symptoms change.
• Home exercise program: Daily balance drills (standing on one foot, heel‑to‑toe walking) and gentle stretching.
• School accommodations: Extra time for assignments, physical‑education modifications, and a 504 plan (U.S.) or equivalent.
• Support groups: Organizations such as the OMS Foundation provide peer‑to‑peer support and resources.
• Medication tracking: Use a pill organizer and a symptom diary to correlate treatment changes with symptom fluctuation.
• Family education: Teach caregivers how to safely assist during falls and how to respond to myoclonic jerks.

Prevention

Because OMS is primarily autoimmune, true primary prevention is limited. However, risk reduction strategies include:

• Early detection and treatment of neuroblastoma or other tumors that may act as antigenic triggers.
• Prompt management of viral infections (e.g., antiviral therapy for influenza) to potentially lower immune activation.
• Maintaining overall immunologic health through adequate sleep, nutrition, and stress management.

Complications

If not adequately treated, OMS can lead to long‑term neurological and functional deficits:

• Permanent ataxia – gait instability that persists into adulthood.
• Cognitive and behavioral sequelae – learning disabilities, attention‑deficit hyperactivity disorder (ADHD), and autism spectrum‑like features.
• Chronic myoclonus – may interfere with daily tasks and cause injury.
• Psychiatric disorders – anxiety, depression, or obsessive‑compulsive behaviors.
• Relapse – up to 30 % of children experience a second episode within 2 years of initial remission (Cleveland Clinic, 2021).

When to Seek Emergency Care

---

© 2024 HealthGuide Media. All information provided is for educational purposes only and does not replace professional medical advice. Consult a qualified health‑care provider for personalized diagnosis and treatment.

```